Genocea Biosciences Inc (GNCAQ)

[NY1972]

Intratumoral CD40 agonist sotigalimab with pembrolizumab induces broad innate and adaptive immune activation in local and distant tumors
There was a robust upregulation of T cells, macrophages, CD8+ T cells, and cytotoxic gene signatures in responders. Additionally, responders had an increase in Th1 gene signatures; an increase in TGF-ß1 gene expression was also noted. In distant lesions, the same gene signatures were upregulated.

https://acir.org/weekly-digests/2022/april/aacr-annual-meeting-2022#therapies